Clinical trials: Typhoid
Salmonella Infections
A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants
The purpose of this study is to evaluate the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid…
- Trial name
- NCT07286370
- Testing
- Low dose of iNTS-TCV, Full dose of iNTS-TCV, TYPHIBEV
- Where
- The Gambia
- Volunteers
- 537 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Typhoid, Paratyphoid Fever
Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam
This study is part of International Vaccine Institutes (IVI)'s typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00131820
- Testing
- Typhoid Vi vaccine, Hepatitis A (control)
- Where
- Vietnam
- Volunteers
- 100,742 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Fever
Effectiveness of a Typhoid Conjugate Vaccine in DRC
This is a prospective cohort evaluation of vaccine effectiveness of a single dose of Typbar-TCV® against symptomatic blood culture-confirmed typhoid fever when administered through a mass vaccination campaign to children 9 months…
- Trial name
- TyVECO (NCT05119426)
- Testing
- Vi-TT
- Where
- 25 sites in Democratic Republic of the Congo
- Volunteers
- 48,000 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Vaccination
CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults
This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever affect the normal immune system and bacteria in the intestine.
- Trial name
- NCT03970304
- Testing
- Vivotif Typhoid Oral Vaccine
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Typhoid Fever
Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana
A cluster-randomised controlled Phase IV trial (cRCT) assessing the impact of a Vi-Polysaccharide conjugate vaccine in preventing typhoid infection in Asante Akim, Ghana (TyVEGHA) with a primary endpoint of determining the total…
- Trial name
- TyVEGHA (NCT04852185)
- Testing
- Vi-TT, MCV-A vaccine
- Where
- Ghana
- Volunteers
- 23,000 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid, Paratyphoid Fever
Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood
This study is part of the International Vaccine Institute's (IVI's) typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries.
- Trial name
- NCT00125047
- Testing
- Typhoid Vi vaccine, Hepatitis A vaccine
- Where
- Pakistan
- Volunteers
- 27,231 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
Typhoid Vaccination, Typhoid
ZyVac-TCV Bangladesh Study
This is a prospective closed cohort, open-label, phase III effectiveness study using a test-negative design of a typhoid conjugate vaccine, ZyVac® TCV (purified Vi capsular polysaccharide of Salmonella Typhi conjugated to tetanus…
- Conditions
- Typhoid Vaccination, Typhoid, Typhoid Fever
- Trial name
- NCT06757283
- Testing
- Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV
- Where
- Bangladesh
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Typhoid Fever
Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old)
This trial is aimed to evaluate the safety and immunogenicity profiles of three formulations of Vi-CRM197 conjugate vaccine against S.
- Trial name
- NCT01193907
- Testing
- NVGH Vi-CRM197 12.5 mcg, NVGH Vi-CRM197 5.0 mcg, NVGH Vi-CRM197 1.25 mcg
- Where
- Belgium
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Novartis